Sex-Specific B Cell and Anti-Myelin Autoantibody Response After Peripheral Nerve Injury

Area of Science:

• Neuroimmunology
• Pain Research
• Immunotherapy

Background:

• Chronic pain states, particularly neuropathic pain, are often refractory to existing treatments.
• Sex differences significantly influence immune responses and pain perception.
• B cells are increasingly recognized for their role in immune regulation and autoimmune processes.

Purpose of the Study:

• To investigate the sex-specific role of B cells in the development of neuropathic pain following peripheral nerve injury.
• To analyze sex differences in immune responses, including autoantibody production and B cell infiltration, after nerve trauma.
• To evaluate the efficacy of B cell depletion therapy in a rat model of neuropathic pain.

Main Methods:

• Utilized a rat model of chronic constriction injury (CCI) to the sciatic nerve.
• Assessed sex differences in myelin basic protein (MBP) epitope release, anti-MBP autoantibodies (IgM/IgG), and endoneurial B cell (CD20+) levels.
• Administered intravenous Rituximab (RTX) or IV immunoglobulin (IVIG) to target B cells and evaluated mechanical allodynia.

Main Results:

• Persistent MBP epitope release was observed in both sexes post-CCI.
• Serum anti-MBP IgM autoantibodies were detected exclusively in female CCI rats.
• Intravenous RTX treatment reduced mechanical allodynia in female rats but not in males; IVIG and vehicle had no effect.

Conclusions:

• Demonstrated significant sexual dimorphism in B cell function and autoimmune pathogenesis of neuropathic pain after peripheral nervous system trauma.
• Suggests that B cell-targeted immunotherapy, particularly RTX, may be a promising non-addictive treatment for chronic pain, especially in females.
• Identified a potential biomarker (myelin-targeted serum autoantibody) for pain states amenable to immunotherapy and highlighted the importance of sex-specific approaches in pain management.